Lumida
/LFVN
⌘K
LifeVantage Corp

LifeVantage Corp

LFVN
$6.20USD+0.32%+0.02 today

MARKET CAP

78.2M

P/E (TTM)

10.3x

FWD P/E

18.7x

DAY RANGE

$6 – $6

52W RANGE

$4
$15

AI Summary

Stalk
StalkMedium

LFVN remains in a Stage 2 advance with medium-term bullish permission, yet the active Post-Parabola Collapse pattern and rejection at the declining short EMAs signal a corrective unwind. Price sits below the 9- and 20-day EMAs and is testing the rising 50-day SMA as support. Immediate entry is unfavorable; waiting for a pullback into the 50-day SMA zone and a clean reclaim of the short EMAs offers a higher-probability bullish engagement.

  • Love Biome acquisition expands gut-health offerings in a segment set to grow from $14.4B to $32.4B by 2035.
  • MindBody GLP-1 system rollout and nutrigenomics supplements diversify revenue streams.
  • Q3 revenue down 25.2% YoY to $43.7M, missing the $48.9M estimate.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

LifeVantage Corporation (NASDAQ:LFVN) specializes in health and wellness products with a focus on nutrigenomics, leveraging its innovative MindBody GLP-1 system among other dietary supplements. Positioned within the rapidly growing wellness market, LifeVantage is actively integrating its recent acquisition of Love Biome, which aims to strengthen its product offerings and develop a more comprehensive health and wellness ecosystem. The company's core strategy emphasizes direct selling and consumer engagement, emphasizing its commitment to expanding its market reach.

Bull says

  • Love Biome acquisition expands gut-health offerings in a segment set to grow from $14.4B to $32.4B by 2035.
  • MindBody GLP-1 system rollout and nutrigenomics supplements diversify revenue streams.
  • Shopify e-commerce integration to enhance customer and consultant sales efficiency.
  • Quarterly dividend up 11% to $0.05 and $60M buyback underline capital return discipline.
  • Some analysts rate it Strong Buy, indicating upside potential despite headwinds.
  • Robust liquidity and attractive dividend yield support stability in volatile markets.

Bear says

  • Q3 revenue down 25.2% YoY to $43.7M, missing the $48.9M estimate.
  • Net income slid to $1.4M (EPS $0.11) from $3.5M (EPS $0.26) a year ago.
  • Active accounts fell 6% to 30,000, signaling consultant engagement risk.
  • Cheaper pharmaceutical GLP-1 alternatives intensify competition and pressure sales.
  • Weak profitability factors and low earnings yield imply constrained return potential.
  • Limited institutional interest and negative momentum reflect market skepticism.

Investment themes with LFVN

Most Shorted Stocks +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q3 2026 · Mgmt. Guidance

Updated 05-10-2026bearish

Transcript signals

Bull points

  • our most recent Momentum Academy in Las Vegas was a great example of this. It perfectly captured the energy and the potential of our consultant community. It was centered around the theme of breakthrough, and this three-day immersive experience brought together our independent consultants and from across the country for powerful leadership training, business building strategies, and meaningful connection with each other.
  • the company announced the VIP bonus, our first ever 12-month volume growth incentive program for consultants. This program will handsomely reward consultants who meet their growth goals, and we believe the program can be a game changer, not only as a catalyst for growth, but also in terms of leadership development.
  • We have a clean balance sheet, no debt, and cash reserves that give us flexibility.

Bear points

  • $43.7 million, which was down 25.2% compared to $58.4 million in the third quarter of fiscal 2025.
  • 28.9% to $34.3 million, reflecting decreased sales of our MindBody GLP-1 system and a decrease in total active accounts.
  • GAAP operating income was 1.7 million compared to 4.1 million in the prior year period. Adjusted non-GAAP operating income was 1.8 million compared to 4.1 million in the prior year period. GAAP net income was 1.4 million, or 11 cents per diluted share, compared to 3.5 million, or 26 cents per diluted share in the prior year period. Adjusted non-GAAP net income was 1.5 million, or 12 cents per diluted share, compared to 3.5 million, or 26 cents per diluted share in the prior year period.
Read full transcript analysis ›